Natriumfusidat “essential Pharma (M)” (Fusidic Acid)

Fusidic acid, the active ingredient in Natriumfusidat “essential Pharma (M)”, is an antibiotic presented as an injection for intravenous use. It treats severe skin and soft‑tissue infections, bone and joint infections, septicemia and other serious infections caused by susceptible Gram‑positive bacteria.

GNH USA supplies Natriumfusidat “essential Pharma (M)” as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide. The company adheres to stringent quality standards and provides reliable, on‑time delivery to healthcare facilities across multiple continents.

Fusidic acid is administered intravenously to manage serious infections caused by susceptible Gram‑positive bacteria.

Severe skin and soft‑tissue infections: provides systemic antibacterial activity that reduces lesion size and promotes healing. Bone and joint infections (osteomyelitis, septic arthritis): eradicates bacterial colonisation in bone tissue, aiding recovery and preventing chronic infection. Septicemia: delivers rapid bacteriostatic effect in the bloodstream, helping to control systemic infection and prevent organ damage. Other serious Gram‑positive infections: offers broad coverage for conditions such as endocarditis or prosthetic device infections when susceptible organisms are identified.

Fusidic acid injection may be associated with several adverse reactions, ranging from mild to severe.

Common Side Effects: - Injection site pain: mild discomfort or erythema at the infusion site. - Rash or pruritus: skin irritation or itching. - Nausea or vomiting: gastrointestinal upset.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction with airway compromise. - Severe hepatic dysfunction: marked elevation of liver enzymes or jaundice. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions.

When using fusidic acid injection, clinicians should observe several precautionary measures to ensure patient safety. - Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic dysfunction: perform baseline and periodic liver function tests. - Known hypersensitivity: avoid use in patients with documented allergy to fusidic acid or related compounds. - Pregnancy and lactation: prescribe only if potential benefit justifies potential risk, as safety data are limited. - Drug interactions: review concomitant medications for possible major or moderate interactions. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Fusidic acid may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Warfarin: increased anticoagulant effect, risk of bleeding. - Cyclosporine: heightened nephrotoxicity when combined. - Rifampicin: reduces fusidic acid plasma concentrations, compromising efficacy.

Moderate Interactions (Monitor Closely): - Statins: potential additive hepatotoxicity; monitor liver enzymes. - NSAIDs: increased risk of gastrointestinal irritation. - Oral contraceptives: possible reduction in contraceptive effectiveness.